0RU5.L

BerGenBio ASA [0RU5.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0RU5.L Stock Summary

In the News

0RU5.L Financial details

Company Rating
-
Market Cap
429.65M
Income
-225.96M
Revenue
389K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-3.8
Forward P/E
-
PEG
3.29
P/S
2184.43
P/B
5.33
P/C
-
P/FCF
-3.13
Quick Ratio
6.33
Current Ratio
7.01
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.35
EPS next Y
-
EPS next Q
-
EPS this Y
-2.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-35.89%
Revenue last 5Y
-30.12%
Revenue Q/Q
-
EPS Q/Q
-92.87%
-
-
-
-
SMA20
-69.65%
SMA50
-84.46%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-120%
ROE
-198%
ROC
-1.39%
Gross Margin
100%
Oper. Margin
-57758%
Profit Margin
-58086%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0774-5.3
52W High
-
52W Low
-
RSI
30.45
Rel Volume
0.06
Avg Volume
238.76K
Volume
14.38K
Perf Week
3.01%
Perf Month
-78.3%
Perf Quarter
-
Perf Half Y
-80%
-
-
-
-
Beta
1.399
-
-
Volatility
0.04%, 2.93%
Prev Close
-3.93%
Price
1.71
Change
-3.93%

Something similar

Top by Market Cap
CMC.DE
V
TL0.DE
EMBASSY.NS
MIX.JO
Same Sector
001630.KS
HITI
OCGN
AGRX
LYS.PA
Check Those
SGL.NS
0F29.L
7864.T
1522.TW
MURGY
Similar Market Cap
8349.HK
NLIT
1838.HK
DIV
DURC-B.ST

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 238.76K
  • Market Capitalization 429.65M
  • Employee 18
  • CEO Mr. Martin Olin
  • Headquarters Bergen,NO
  • IPO Date 2017-12-13
  • Website https://www.bergenbio.com

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.